InsidersTradesSigma
Total declarations
Company
▲ Purchases (4 ops.)
▼ Sales (0 ops.)
Browse the full record of transactions filed by Greene Barry E, Chairman & CEO. Officer active across 1 companies, notably Sage Therapeutics, Inc.. In total, 4 reports have been published. Total volume traded: €2.6m. The latest transaction was disclosed on 5 August 2021 — Acquisition. Regulator: SEC (Form 4). All data is free.
Declarations4 total
€861,84423,640 shares@ €36.45767.6% of flow
Common Stock
SEC:0001562180-21-005226·
Ideal exit: 2 May 2022 (T+270)
€861,84423,640 shares@ €36.45733.8% of flow
Common Stock
SEC:0001562180-21-005226:0·
Ideal exit: 2 May 2022 (T+270)
€413,1758,800 shares@ €46.951732.4% of flow
Common Stock
SEC:0001562180-21-004342·
Ideal exit: 13 Mar 2022 (T+270)
€413,1758,800 shares@ €46.951716.2% of flow
Common Stock
SEC:0001562180-21-004342:0·
Ideal exit: 13 Mar 2022 (T+270)
4 of 4 declarations
About Greene Barry E
Barry E. Greene is the President and CEO of Sage Therapeutics, Inc. He leads the company with a focus on innovation in healthcare. Under his leadership, Sage Therapeutics is committed to developing innovative treatments for patients.
